Novo Nordisk said the FDA is updating labeling for Victoza to include a clinical finding that the type 2 diabetes medicine is superior to Merck & Co.'s Januvia in terms of glucose control and weight loss. The label also reflects approved use of Victoza in combination with basal insulin.

Full Story:

Related Summaries